About DynaSci
Team
Mr. Levent is a pharmaceutical veteran with more than 25 years of pharma industry experience across Central & Eastern Europe and Middle East & North Africa. Levent was the previous CEO and Chairman of Mustafa Nevzat Pharma (“MN Pharma”), the leading injectable generics pharmaceutical company in CEE. MN Pharma was the first and only company to receive US FDA approval in Turkey and was responsible for the launch and commercialisation of the first biosimilar product in Turkey. MN Pharma was sold to Amgen, one of the world’s largest biotechnology companies, for $700m in 2012. At the time of sale, MN Pharma was fully integrated (including API production), employed 1,200 people and generated approximately $200m in annual revenue. Levent is a non-executive Board Member of Phamactive (generic pharma), Imuneks Pharma (OTC) and Polus Global (Korean biosimilar company). Levent was also recently a senior advisor to Polpharma and currently leads Frontier Pharma’s advisory board.
Mehmet Pisak has deep experience in leading and managing a large pharma business and has assembled a skilled and motivated team to execute the DynaSci vision/strategy alongside him. With a successful exit to his name, he is also well-placed to understand the needs of investors and the evolution of the market. Mr. Pisak has been involved in all aspects of the industry; he has patented several new treatment modalities and has overseen the development and commercialization of more than 30 products ranging from oral to injectable, OTC to Rx . Additionally, he has also realized multiple in-licensing and out-licensing deals, including the out-licensing and sale of a regional blockbuster to a big Pharma company. Furthermore, he has also supervised the construction of an injectable oncolytics plant, including all technical procurement, as a Greenfield project (FDA approved). Finally, he was heavily involved with the sale of MN Pharmaceuticals to Amgen at a record setting 17X EBIDTA multiplier. His past and present experience makes him very well placed to repeat his success with DynaSci, for which he has personally invested 8,5 million USD to reach this stage of the development cycle.
Dr. Aydogan holds a Ph.D. and M.D. from the University of Cologne, Germany with a special emphasis on glycoproteins and immunology. With over two decades of experience in the pharmaceutical and nutrition industries, Dr. Aydogan combines a unique experience of being a scientist, a physician and management professional. After receiving his degrees, Dr. Aydogan practiced as physician in the department of Endocrinology at the Faculty of Medicine in Cologne. Since then, Dr. Aydogan has held management positions in the pharmaceutical and nutrition industries, with companies like Johnson&Johnson, and Frutarom/ICC Industries. He is the founder of Bluestone Pharma, a company supplying special pro-biotics for special indications, Nouvellune GmbH, a company supplying novel innovative supplements globally and is currently the CEO of PhytoNet AG, a Swiss-based company providing international consulting and business development/sales services in the pharmaceutical, OTC and dietary supplement industries.
Mr. Can Duna has 16 years of Emerging Markets sales & advisory experience across varied products (ranging from VC, PE to M&A, but also Government and Policy Affairs, to general Management and Financial advisory) having worked at Garanti Bank International, Lehman Brothers and as a Managing Partner at AB Consultancy. He is a graduate of the Lycée Français Pierre Loti and received his BS from Brown University in 2003
Mr. Hakan Ansen has 19 years of Emerging Markets sales & structuring experience across Global Markets products (capital markets, client financing, credit, rates, foreign exchange, local markets and commodities) having worked for Bankers Trust A.S., Lehman Brothers International (Europe), Deutsche Bank AG London, Standard Bank Plc and Unlu & Co. during his career. He is a graduate of Robert College and received his BS from Massachusetts Institute of Technology in 1995 and his MBA from Columbia Business School in 1999
Mr. Yalçın Sisa has 15 years of marketing and communications experience both in off and online media channels. He previously worked for Stroer, one of the leading Out of Home Media Company’s, and was responsible for further developing sales, and, creating new and alternative sales channels. Previously to that, he worked in Turkey’s leading outdoor production company CIPS Production as a sales and operations director. Worked with Reckitt Benckiser, Netflix, Vodafone and Coca –Cola. Recently, he founded a media purchasing agency, Mediatic, acting both for digital and offline marketing activities in 2011.
Advisory Board
Samir Abhyankar is a Private Equity professional with 20 years’ experience. He was a Partner at TPG Growth($8BN AuM) and TPG Rise Fund ($2.0 BN Impact Fund) based in London, where he worked across sectors covering the group’s investment activities in Africa. – He helped set up TPG’s activities in Africa. Focus sectors included Social Infrastructure, Financial Services, Food and Agriculture. Prior to joining the firm in 2015, Samir was a Partner at Satya Capital and a Vice President at Citi Venture Capital International. Samir graduated with an MBA from INSEAD and holds an MA from John’s Hopkins’ School of Advanced International Studies.
Kiren is a former pharmaceutical industry-focused investment banker, most recently a senior Vice President at Bank of America Merrill Lynch in Johannesburg and London. Kiren’s expertise spans strategic and financial advisory (covering mergers & acquisitions and business development) and capital raising activities (across debt, equity and hybrid products). Kiren’s pharma expertise covers branded generics, specialty pharma and consumer health. Some of Kiren’s most notable transactions include: Sale of MN Pharma to Amgen ($700m), Sale of Bedford Laboratories (owned by Boehringer Ingelheim) to Hikma ($300m), Swap of Boehringer Ingelheim’s Consumer Healthcare Business with Sanofi’s Animal Health Business (Merial) (€22bn) and the Financing of Teva’s $40.5bn acquisition of Allergan Generics (Actavis). Kiren also leads Frontier Pharma’s advisory activities in Central and Eastern Europe, Russia / CIS, Middle East / North Africa, sub-Saharan Africa and Central America.
Ömer graduated from Bilgi university Law School in 2010 and completed Bussines Law LLM at UC Berkeley School of Law in 2015. He supports domestic and international clients with
corporate counseling matters related to their daily business. His work includes drafting, revision and negotiation of contracts such as share purchase and shareholders agreements, distributorship and so forth. Ömer prepares tailor made legal memorandums on subjects requested by clients with a special interest on e-commerce. He maintains an active arbitration and litigation practice and specializes on goodwill (portfolio) compensation along with disputes arising out of international carriage of goods. Ömer is also a sworn translator in English and Italian languages.
Ömer also acts as a Mediator registered to Mediator’s Registr
corporate counseling matters related to their daily business. His work includes drafting, revision and negotiation of contracts such as share purchase and shareholders agreements, distributorship and so forth. Ömer prepares tailor made legal memorandums on subjects requested by clients with a special interest on e-commerce. He maintains an active arbitration and litigation practice and specializes on goodwill (portfolio) compensation along with disputes arising out of international carriage of goods. Ömer is also a sworn translator in English and Italian languages.
Ömer also acts as a Mediator registered to Mediator’s Registr